Collaboration Revenue - Additional Information (Details) - USD ($) $ in Thousands		12 Months Ended
	Jul. 01, 2021	Dec. 31, 2021	Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total consideration		$ 143,645
Strategic Collaboration Agreement with Pharming
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Cash upfront payment received	$ 10,000
Strategic Collaboration Agreement with Pharming | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments receivable	189,500
Share Purchase Agreement with Pharming
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total consideration	$ 7,500
Issuance of ordinary shares	1,227,738
Common stock consideration	$ 4,100
Premium consideration	3,400
Pharming Agreements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total upfront payments	17,500
Upfront payments attributed to equity sold	4,100
Upfront payments attributed to research activities	13,400
Estimated reimbursement payments	$ 13,400
Collaborative Arrangement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contract liabilities			$ 11,300
Contract liabilities current			1,000
Contract liabilities non current			10,300
Collaborative Arrangement | Accounts Receivable
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Accounts receivable		$ 800	$ 500